Must agree to use acceptable contraceptive methods through at least 90 days after the last dose of study drug.
Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/ m2.
Willing to comply with the study requirements and to provide written informed consent.
You may not be if
Infected with hepatitis B virus, hepatitis C virus, HIV.
Abuse of alcohol or drugs.
Use of other investigational drugs within 28 days prior to Day -5.
Concomitant use of prescription medications, or systemic over-the-counter medications (apart from methadone or buprenorphine/naloxone as assigned maintenance therapy).
Other clinically significant medical conditions or laboratory abnormalities.
Clareo Health | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
